Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation

Seminars in Hematology

Volumn 49, Issue 1, 2012, Pages 35-42

  Brissot, Eolia ^a,b   Savani, Bipin N ^c   Mohty, Mohamad ^a,b,d  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Team 12   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CALCINEURIN INHIBITOR; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERIPROX; FERRITIN; UNCLASSIFIED DRUG;

ALCOHOLISM; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CREATININE BLOOD LEVEL; DYSERYTHROPOIESIS; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEART MUSCLE BIOPSY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERFERRITINEMIA; INFLAMMATION; IRON DEPLETION; IRON OVERLOAD; KIDNEY DISEASE; LIVER BIOPSY; LIVER FIBROSIS; LONG TERM SURVIVAL; LONG TERM SURVIVOR; METABOLIC SYNDROME X; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOTOMY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SURVIVOR;

FERRITINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON OVERLOAD; SURVIVORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855374113     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.10.003     Document Type: Article

References (65)

1. Wingard J.R., Majhail N.S., Brazauskas R., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011, 29:2230-2239.
2. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005, 352:1769-1778.
3. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006, 37:249-261.
4. Le Lan C., Loreal O., Cohen T., et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005, 105:4527-4531.
5. Adams P.C., Barton J.C. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 2011, 55:453-458.
6. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
7. Grundy S.M., Hansen B., Smith S.C., Cleeman J.I., Kahn R.A. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109:551-556.
8. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
9. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
10. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
11. Mendler M.H., Turlin B., Moirand R., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999, 117:1155-1163.
12. Baker K.S., Ness K.K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007, 109:1765-1772.
13. Tichelli A., Bhatia S., Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008, 142:11-26.
14. Tichelli A., Bucher C., Rovo A., et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007, 110:3463-3471.
15. Moirand R., Kerdavid F., Loreal O., et al. Regulation of ferritin expression by alcohol in a human hepatoblastoma cell line and in rat hepatocyte cultures. J Hepatol 1995, 23:431-439.
16. Aguilar-Martinez P., Schved J.F., Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol 2005, 100:1185-1194.
17. McDonald G.B. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010, 51:1450-1460.
18. Strasser S.I., Myerson D., Spurgeon C.L., et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999, 29:1893-1899.
19. Strasser S.I., Shulman H.M., Flowers M.E., et al. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology 2000, 32:1265-1271.
20. Majhail N.S., Lazarus H.M., Burns L.J. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008, 41:997-1003.
21. Porter J.B. Practical management of iron overload. Br J Haematol 2001, 115:239-252.
22. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007, 13:1096-1101.
23. Pootrakul P., Breuer W., Sametband M., Sirankapracha P., Hershko C., Cabantchik Z.I. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004, 104:1504-1510.
24. Piperno A. Classification and diagnosis of iron overload. Haematologica 1998, 83:447-455.
25. Chotsampancharoen T., Gan K., Kasow K.A., Barfield R.C., Hale G.A., Leung W. Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 2009, 13:348-352.
26. Rose C., Ernst O., Hecquet B., et al. Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long term survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Haematologica 2007, 92:850-853.
27. Kamble R.T., Selby G.B., Mims M., Kharfan-Dabaja M.A., Ozer H., George J.N. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:506-510.
28. Sucak G.T., Yegin Z.A., Ozkurt Z.N., Aki S.Z., Karakan T., Akyol G. The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated?. Bone Marrow Transplant 2008, 42:461-467.
29. Schafer A.I., Cheron R.G., Dluhy R., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981, 304:319-324.
30. Di Tucci A.A., Matta G., Deplano S., et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008, 93:1385-1388.
31. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
32. Malcovati L., Della Porta M.G., Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006, 91:1588-1590.
33. Angelucci E., Muretto P., Nicolucci A., et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002, 100:17-21.
34. Mariotti E., Angelucci E., Agostini A., Baronciani D., Sgarbi E., Lucarelli G. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol 1998, 103:916-921.
35. Majhail N.S., Lazarus H.M., Burns L.J. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 2010, 16:832-837.
36. Angelucci E., Brittenham G.M., McLaren C.E., et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000, 343:327-331.
37. Oshrine B., Lehmann L.E., Duncan C.N. Safety and utility of liver biopsy after pediatric hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2011, 33:e92-e97.
38. Wood J.C., Enriquez C., Ghugre N., et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
39. Gandon Y., Olivie D., Guyader D., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004, 363:357-362.
40. Hankins J.S., McCarville M.B., Loeffler R.B., et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009, 113:4853-4855.
41. Mavrogeni S.I., Markussis V., Kaklamanis L., et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol 2005, 75:241-247.
42. Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation. xx;123:1519-28.
43. Kirk P., Roughton M., Porter J.B., et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009, 120:1961-1968.
44. Noetzli L.J., Carson S.M., Nord A.S., Coates T.D., Wood J.C. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008, 112:2973-2978.
45. Au W.Y., Lam W.M., Chu W.C., et al. A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels. Transplant Proc 2007, 39:3369-3374.
46. Majhail N.S., DeFor T., Lazarus H.M., Burns L.J. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant 2008, 14:790-794.
47. Tomas J.F., Pinilla I., Garcia-Buey M.L., et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 2000, 26:649-655.
48. Lucarelli G., Angelucci E., Giardini C., et al. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet 1993, 342:1388-1391.
49. Muretto P., Del Fiasco S., Angelucci E., De Rosa F., Lucarelli G. Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting. Liver 1994, 14:14-24.
50. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010, 95:476-484.
51. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
52. McKay P.J., Murphy J.A., Cameron S., et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996, 17:63-66.
53. Busca A., Falda M., Manzini P., et al. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant 2010, 16:115-122.
54. Angelucci E., Muretto P., Lucarelli G., et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997, 90:994-998.
55. Li C.K., Lai D.H., Shing M.M., Chik K.W., Lee V., Yuen P.M. Early iron reduction programme for thalassaemia patients after bone marrow transplantation. Bone Marrow Transplant 2000, 25:653-656.
56. Giardini C., Galimberti M., Lucarelli G., et al. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. Br J Haematol 1995, 89:868-873.
57. Kaloyannidis P., Yannaki E., Sakellari I., et al. The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis. Transplantation 2010, 89:472-479.
58. Hoke E.M., Maylock C.A., Shacter E. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med 2005, 39:403-411.
59. Donfrancesco A., De Bernardi B., Carli M., et al. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. Eur J Cancer 1995, 31A:612-615.
60. Richardson D.R. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 2002, 42:267-281.
61. Pennell D.J., Berdoukas V., Karagiorga M., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006, 107:3738-3744.
62. Smith G.C., Alpendurada F., Carpenter J.P., et al. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson 2011, 13:34.
63. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895-902.
64. Kanda J, Mizumoto C, Ichinohe T, et al. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. XX;46:208-16.
65. Sucak G.T., Yegin Z.A., Ozkurt Z.N., Aki S.Z., Yagci M. Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation. Transplant Proc 2010, 42:1841-1848.